News coverage about EXACT Sciences (NASDAQ:EXAS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. EXACT Sciences earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.5537410046488 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Unpredictable Volume Exact Sciences Corporation’s (EXAS) (getstocksnews.com)
- Notable Traders Recap: Exact Sciences Corporation, (NASDAQ: EXAS), Dover Corporation, (NYSE: DOV) (globalexportlines.com)
- EXACT Sciences (EXAS) Lifted to Strong-Buy at Vetr (americanbankingnews.com)
- EXACT Sciences (EXAS) Upgraded to “Buy” by BidaskClub (americanbankingnews.com)
- Baird: Exact Sciences Should Rebound After First-Quarter ‘Headwinds’ (xconomy.com)
Shares of EXAS stock traded down $1.77 on Tuesday, hitting $46.93. 3,412,746 shares of the stock traded hands, compared to its average volume of 2,859,170. The company has a current ratio of 7.15, a quick ratio of 6.77 and a debt-to-equity ratio of 0.01. The stock has a market cap of $5,747.14, a price-to-earnings ratio of -47.40 and a beta of 0.87. EXACT Sciences has a twelve month low of $23.71 and a twelve month high of $63.60.
EXAS has been the topic of a number of research analyst reports. BTIG Research raised shares of EXACT Sciences from a “neutral” rating to a “buy” rating in a research note on Tuesday, April 3rd. Zacks Investment Research raised shares of EXACT Sciences from a “sell” rating to a “hold” rating in a research note on Monday, March 19th. BidaskClub raised shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 7th. Benchmark set a $65.00 target price on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Finally, ValuEngine raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. EXACT Sciences currently has an average rating of “Buy” and a consensus target price of $52.84.
In other news, insider Kevin T. Conroy sold 101,488 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $45.72, for a total transaction of $4,640,031.36. Following the transaction, the insider now owns 931,540 shares of the company’s stock, valued at approximately $42,590,008.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP D Scott Coward sold 2,122 shares of the business’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $40.12, for a total transaction of $85,134.64. The disclosure for this sale can be found here. In the last three months, insiders have sold 229,834 shares of company stock worth $10,341,366. Corporate insiders own 4.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Week Herald and is the property of of Week Herald. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://weekherald.com/2018/04/25/exact-sciences-exas-receiving-somewhat-positive-media-coverage-accern-reports.html.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.